Trial Profile

Alendronic acid versus teriparatide in women with postmenopausal osteoporosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teriparatide (Primary) ; Alendronic acid
Indications Fracture; Postmenopausal osteoporosis
Focus Pharmacodynamics
Acronyms FACT
Sponsors Eli Lilly and Company

Most Recent Events

20 Dec 2011 Not official study title
08 Nov 2011 Results of an analysis of bone remodelling parameters (n=21) presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com